Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein

Environmental Toxicology and Pharmacology

Volumn 1, Issue 1, 1996, Pages 63-72

  Chao, Chuck C K ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Drug efflux; Immunoblastic lymphoma; Muldrug resistance; P glycoprotein

Indexed keywords

CISPLATIN; COLCHICINE; DOXORUBICIN; GLYCOPROTEIN P; MITOMYCIN C; PUROMYCIN; RADIOISOTOPE; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CELL LINE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLAST; IMMUNOBLOTTING; LUNG CANCER; LYMPHOMA CELL; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030007291     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/1382-6689(95)00010-0     Document Type: Article

References (48)

1. Almquist, K.R., D.W. Loe, D.R. Hipfner, J.E. Mackie, S.P.C. Cole and R.G. Deeley, 1995, Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selcted and transfected human tumor cells, Cancer Res. 55, 102-110.
2. Batist, G., A. Tulpule, B. Sinha, A. Katki, C. Meyer and K. Cowan, 1986, Overexpression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells, J. Biol. Chem. 261, 15544-15549.
3. Bernheim, A., R. Berger and G. Lenoir, 1981, Cytogenetic studies on African Burkitt's lymphoma cell lines: t(8:14), t(2:8) and t(8:22) translocations, Cancer Genet. Cytogenet. 3, 307-315.
4. Binetruy, B., T. Smeal and M. Karin, 1991, Ha-ras augments c-jun activity and stimulates phosphorylation of its activation domain, Nature 351, 122-126.
5. Bishop, J.M., 1991, Molecular themes in oncogenesis, Cell 64, 235-248.
6. Bradley, G., P.F. Juranka and V. Ling, 1988, Mechanism of multidrug-resistance, Biophys. Biochem. Acta 948, 87-128.
7. Burt, R.K., S. Garfield, K. Johnson and S.S. Thorgeirsson, 1988, Transformation of rat epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals, Carcinogenesis 9, 2329-2332.
8. Chaganti, R.S.K., 1983, Significance of chromosome change to hematopoietic neoplasms, Blood 62, 515-518.
9. Chao, C.C.-K., 1994, Deceased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair, Mol. Pharmacol. 45, 1137-1144.
10. Chao, C.C.-K., Y.-T. Huang, C.M. Ma, W.-Y. Chou and S. Lin-Chao, 1992, Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line, Mol. Pharmacol. 41, 69-75.
11. Chao, C.C.-K., W.-C. Yam and Y.-S. Ho., 1995, Adriamycin-inducible proteins associated with drug sensitivity in resistant immunoblastic B lymphoma cells, Mutat. Res. 346, 33-41.
12. Chen, C.-J., J.E. Chin, K. Ueda, D.P. Clark, I. Pastan, M.M. Gottesman and I.B. Roninson, 1986, Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells, Cell 47, 381-389.
13. Chiang, C.D., E.-J. Song, V.C. Yang and C.C.-K. Chao, 1994, Ascorbic acid increases drug accumulation and reverses vincristine resistance on human non-small-cell lung cancer cells, Biochem. J. 301, 759-764.
14. Choi, K., C.-j. Chen, M. Kriegler and I.B. Roninson, 1988, An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutation in the mdr1 (P-glycoprotein) gene, Cell 53, 519-529.
15. Chung, D.L., P.W. Brandt-Rauf, I.B. Weinstein, S. Nishimura, Z. Yamaizumi, R.B. Murphy and M.R. Pincus, 1992, Evidence that the ras oncogene-encoded p21 protein induces oocyte maturation via activation of protein kinase C, Proc. Natl Acad. Sci. USA 89, 1993-1996.
16. Cole, S.P.C., E.R. Chanda, F.P. Dicke, J.H. Gerlach and S.E.L. Mirski, 1991. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II, Cancer Res. 51, 3345-3352.
17. Cole, S.P.C., G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Gant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Duncan and R.J. Deeley, 1992. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line, Science 258, 1650-1654.
18. Cowan, K.H., G. Batist, A. Tulpule, B.K. Sinha and C.E. Meyer, 1986, Similar biochemical changes associated with acquiredresistance to antineoplastic drugs in human breast cancer cells and with resistance to xenobiotics induced by carcinogens in rat hepatocytes, Proc. Natl Acad. Sci. USA 83, 9328-9332.
19. Endicott, J.A. and V. Ling, 1989, The biochemistry of P-glycoprotein-mediated multidrug resistance, Annu. Rev. Biochem. 58, 137-171.
20. Fairchild, C.R., S.P. Ivy, C.S. Kao-Shang, J. Whang-Peng, N. Rosen, M.A. Israel, P.W. Melera, K.H. Cowan and L. goldsmith, 1987, Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells, Cancer Res. 47, 5141-5148.
21. Fojo, A., M. Cornwell, C. Cardarelli, D.P. Clark, N. Richert, D. Shen, K. Ueda, M. Williangham, M. Gottesman and I. Pastan, 1987, Molecular biology of drug resistance, Breast Cancer Res. 9, 5-16.
22. Georges, E., G. Bradley, J. Gariepy and V. Ling, 1990, Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies, Proc. Natl. Acad. Sci. USA 87, 152-156.
23. Gerlach, J., N. Kartner, D. Bell and V. Ling, 1986, Multidrug resistance, Cancer Surv. 5, 25-46.
24. Gottesman, M.M. and I. Pastan, 1989, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu. Rev. Biochem. 62, 385-427.
25. Grant, C.E., G. Valdimarsson, D.R. Hipfner, K.C. Almquist, S.P.C. Cole and R.G. Deeley, 1994, Overexpression of multidrug resistance protein (MRP) increases resistance to natural product drugs, Cancer Res. 54, 357-361.
26. 2-microglobulin gene, primary structure and defination of the transcriptional unit, J. Immunol. 139, 3132-3138.
27. Haliotis, T., W. Trimble, S. Chow, S. Bull, G. Mills, P. Girard, J.F. Kuo and N. Hozumi, 1990, Expression of ras oncogene leads to down-regulation of protein kinase C, Int. J. Cancer 45, 1177-1183.
28. Harlow, E. and D. Lane, 1988, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
29. Hill, B.T., 1993, Differing patterns of cross-resistance resulting from exposure to specific antitumour drugs to radiation in vitro, Cytotechnology 12, 265-288.
30. Ho, Y.-S., L.-F. Sheu, J.-A. Ng and S.-M. Hsu, 1990, Establishment and characterisation of an Epstain-Barr virus negative B immunoblastic lymphoma cell line, Br. J. Cancer 61, 655-658.
31. Inaba, M., H. Kobayashi, Y. Sakurai and R.K. Johnson, 1979, Active efflux of daunorubicin and Adriamycin in sensitive and resistant sublines of P388 leukemia, Cancer Res. 39, 2200-2203.
32. Kirschner, L.S., L.M. Greenberger, S.I.-H. Hsu, C.-P.H. Yang, D. Cohen, R.L. Piekarz, G. Gastillo, E.K.-H. Han, L. Yu and S.B. Horwitz, 1992, Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells, Biochem. Pharmacol. 43, 77-87.
33. Laemmli, U.K., 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227, 680-685.
34. Lemontt, J.F., M. Azzaria and P. Gros, 1988, Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Res. 48, 6348-6353.
35. Lenoir, G.M., J.L. Preud'homne, A. Bernheim and R. Berger, 1982, Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma, Nature 298, 474-481.
36. Levy, E., C. Baroche, J.M. Barret, C. Alapetite, B. Salles, D. Averbeck and E. Moustacchi, 1994, Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair, Carcinogenesis 15, 845-850.
37. Manalov, G. and Y. Manalov, 1972, Marker band in one chromosome 14 from Burkitt's lymphoma, Nature 237, 33-40.
38. Mirski, S.E.L., J.H. Gerlach and S.P.C. Cole, 1987, Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin, Cancer Res. 47, 2594-2598.
39. Mosmann, T., 1983, Rapid colormetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63.
40. Murren, J.R. and W.N. Hait, 1992, Why haven't we cured multidrug resistant tumors?, Oncol. Res. 4, 1-6.
41. Niimi, S., K. Nakagawa, J. Yokota, Y. Tsunokawa, K. Nishio, Y. Terashima, M. Shibuya, M. Terada and N. Saijo, 1991, Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes, Br. J. Cancer 63, 237-241.
42. Perez, R.P., K. Hamaguchi, P.A. Tracey, L.M. Handel, T.C. Hamilton and A.K. Godwin, 1993, Transformation of rat ovarian epithelial and rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity, Cancer Res. 53, 3771-3775.
43. Riodan, J.R. and V. Ling, 1979, Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster cell mutants with reduced colchicine permeability, J. Biol. Chem. 254, 12701-12705.
44. Sambrook, J., E.F. Fritsch and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
45. Scanlon, K.J., M. Kashani-Sabet, H. Miyachi, L.C. Sowers and J. Rossi, 1989, Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res. 9, 1301-1312.
46. Sklar, M.D., 1988, Increased resistance to cis-diamminedichloroplatinum(II) in NIH3T3 cells transformed by ras oncogenes, Cancer Res. 48, 793-797.
47. Tofolli, G., A. Viel, L. Tumiotto, P. Buttagi, G. Biscontin and M. Boiocchi, 1989, Sensitivity pattern of normal and H-ras transformed NIH3T3 fibroblasts to antineoplastic drugs, Tumori 75, 423-428.
48. Zech, L., V. Haglund, N. Nilsson and G. Klein, 1976, Characteristic chromosome abnormalities in biopsies and lymphoid cell lines from patients with Burkitt's and non-Burkitt's lymphoma, Int. J. Cancer 17, 47-56.